Remote symptom-monitoring app for people on chemotherapy
Feasibility and Acceptability of the Remote Oncology Symptom Assessment Application
This project will test a smartphone app that combines activity data and daily symptom reports to see if it helps adults with solid tumor cancers manage symptoms during chemotherapy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Pittsburgh Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Pittsburgh, Pennsylvania) |
| Trial ID | NCT07218874 on ClinicalTrials.gov |
What this trial studies
The study will enroll 50 adults receiving chemotherapy for solid tumors at UPMC Hillman Cancer Center to use the ROSA app and wear a Fitbit for 90 days. Participants will complete daily symptom ratings and quality-of-life questionnaires at baseline, midpoint, and end of study, with an optional in-person physical function assessment. The app securely transmits de-identified sensor and patient-reported data to a cloud server and generates alerts and care-team contact recommendations. Investigators will review medical records for clinical covariates and conduct a semi-structured exit interview to measure feasibility and acceptability.
Who should consider this trial
Good fit: Adults (18+) receiving chemotherapy for any solid tumor at UPMC Hillman with at least two cycles remaining, who read and write English, have sufficient performance status (Karnofsky ≥60), and own a compatible Android or iPhone.
Not a fit: People without a compatible smartphone, who cannot read English, who have poor performance status, or who are not receiving care at the recruiting center are unlikely to benefit or be eligible.
Why it matters
Potential benefit: If successful, the app could prompt earlier care-team intervention, reduce severe side effects, and improve patients' quality of life during chemotherapy.
How similar studies have performed: Previous trials of remote symptom monitoring in oncology have shown promising results such as improved quality of life and fewer emergency visits, so this study builds on existing but not yet definitive evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Receiving chemotherapy at the UPMC Hillman Cancer Center for any solid tumor cancer at any stage with at least two cycles remaining; * age 18 years or older; * ability to read and write in English; * sufficient performance status to participate in research (e.g., Karnofsky performance status of 60-100%); and * owns and uses an Android smartphone or an iPhone capable of running the study apps. Exclusion Criteria: * under 18 years old; and * unable to read and write in English
Where this trial is running
Pittsburgh, Pennsylvania
- UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania, United States (Recruiting)
Study contacts
- Principal investigator: Carissa A Low — University of Pittsburgh
- Study coordinator: Carissa A Low
- Email: lowca@upmc.edu
- Phone: (412) 623-5973
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.